Patents by Inventor Sabine Arndt

Sabine Arndt has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 9689022
    Abstract: The invention provides methods and compositions for the rapid and sensitive detection of post-translationally modified proteins, and particularly of those with posttranslational glycosylations. The methods can be used to detect O-GlcNAc posttranslational modifications on proteins on which such modifications were undetectable using other techniques. In one embodiment, the method exploits the ability of an engine˜red mutant of ?-1,4-galactosyltransferase to selectively transfer an unnatural ketone functionality onto O-GlcNAc glycosylated proteins. Once transferred, the ketone moiety serves as a versatile handle for the attachment of biotin, thereby enabling detection of the modified protein. The approach permits the rapid visualization of proteins that are at the limits of detection using traditional methods. Further, the preferred embodiments can be used for detection of certain disease states, such as cancer, Alzheimer's disease, neurodegeneration, cardiovascular disease, and diabetes.
    Type: Grant
    Filed: December 23, 2014
    Date of Patent: June 27, 2017
    Assignee: California Institute of Technology
    Inventors: Linda Hsieh-Wilson, Nelly Khidekel, Hwan-Ching Tai, Sabine Arndt
  • Publication number: 20150344932
    Abstract: The invention provides methods and compositions for the rapid and sensitive detection of post-translationally modified proteins, and particularly of those with posttranslational glycosylations. The methods can be used to detect O-GlcNAc posttranslational modifications on proteins on which such modifications were undetectable using other techniques. In one embodiment, the method exploits the ability of an engine˜red mutant of ?-1,4-galactosyltransferase to selectively transfer an unnatural ketone functionality onto O-GlcNAc glycosylated proteins. Once transferred, the ketone moiety serves as a versatile handle for the attachment of biotin, thereby enabling detection of the modified protein. The approach permits the rapid visualization of proteins that are at the limits of detection using traditional methods. Further, the preferred embodiments can be used for detection of certain disease states, such as cancer, Alzheimer's disease, neurodegeneration, cardiovascular disease, and diabetes.
    Type: Application
    Filed: December 23, 2014
    Publication date: December 3, 2015
    Applicant: CALIFORNIA INSTITUTE OF TECHNOLOGY
    Inventors: LINDA HSIEH-WILSON, NELLY KHIDEKEL, HWAN-CHING TAI, SABINE ARNDT
  • Patent number: 8927300
    Abstract: The invention provides methods and compositions for the rapid and sensitive detection of post-translationally modified proteins, and particularly of those with posttranslational glycosylations. The methods can be used to detect O-GlcNAc posttranslational modifications on proteins on which such modifications were undetectable using other techniques. In one embodiment, the method exploits the ability of an engine˜red mutant of ?-1,4-galactosyltransferase to selectively transfer an unnatural ketone functionality onto O-GlcNAc glycosylated proteins. Once transferred, the ketone moiety serves as a versatile handle for the attachment of biotin, thereby enabling detection of the modified protein. The approach permits the rapid visualization of proteins that are at the limits of detection using traditional methods. Further, the preferred embodiments can be used for detection of certain disease states, such as cancer, Alzheimer's disease, neurodegeneration, cardiovascular disease, and diabetes.
    Type: Grant
    Filed: February 22, 2013
    Date of Patent: January 6, 2015
    Assignee: California Institute of Technology
    Inventors: Linda Hsieh-Wilson, Nelly Khidekel, Hwan-Ching Tai, Sabine Arndt
  • Patent number: 8691850
    Abstract: The present application relates to novel phenylaminothiazole derivatives, to processes for their preparation, to their use for the treatment and/or prophylaxis of diseases and to their use for preparing medicaments for the treatment and/or prophylaxis of diseases, preferably for the treatment and/or prevention of hypertension and other cardiovascular disorders.
    Type: Grant
    Filed: August 30, 2005
    Date of Patent: April 8, 2014
    Assignee: Bayer Intellectual Property GmbH
    Inventors: Jens-Kerim Ergüden, Gunter Karig, Ulrich Rosentreter, Barbara Albrecht, Kerstin Henninger, Joachim Hütter, Nicole Diedrichs, Peter Nell, Sabine Arndt, Walter Hübsch, Andreas Knorr, Karl-Heinz Schlemmer, Dirk Brohm
  • Patent number: 8383425
    Abstract: The invention provides methods and compositions for the rapid and sensitive detection of post-translationally modified proteins, and particularly of those with post-translational glycosylations. The methods can be used to detect O-GlcNAc posttranslational modifications on proteins on which such modifications were undetectable using other techniques. In one embodiment, the method exploits the ability of an engineered mutant of ?-1,4-galactosyltransferase to selectively transfer an unnatural ketone functionality onto O-GlcNAc glycosylated proteins. Once transferred, the ketone moiety serves as a versatile handle for the attachment of biotin, thereby enabling detection of the modified protein. The approach permits the rapid visualization of proteins that are at the limits of detection using traditional methods. Further, the preferred embodiments can be used for detection of certain disease states, such as cancer, Alzheimer's disease, neurodegeneration, cardiovascular disease, and diabetes.
    Type: Grant
    Filed: October 21, 2010
    Date of Patent: February 26, 2013
    Assignee: California Institute of Technology
    Inventors: Linda Hsieh-Wilson, Nelly Khidekel, Hwan-Ching Tai, Sabine Arndt
  • Publication number: 20110217732
    Abstract: The invention provides methods and compositions for the rapid and sensitive detection of post-translationally modified proteins, and particularly of those with post-translational glycosylations. The methods can be used to detect O-GlcNAc posttranslational modifications on proteins on which such modifications were undetectable using other techniques. In one embodiment, the method exploits the ability of an engineered mutant of ?-1,4-galactosyltransferase to selectively transfer an unnatural ketone functionality onto O-GlcNAc glycosylated proteins. Once transferred, the ketone moiety serves as a versatile handle for the attachment of biotin, thereby enabling detection of the modified protein. The approach permits the rapid visualization of proteins that are at the limits of detection using traditional methods. Further, the preferred embodiments can be used for detection of certain disease states, such as cancer, Alzheimer's disease, neurodegeneration, cardiovascular disease, and diabetes.
    Type: Application
    Filed: October 21, 2010
    Publication date: September 8, 2011
    Applicant: CALIFORNIA INSTITUTE OF TECHNOLOGY
    Inventors: LINDA HSIEH-WILSON, NELLY KHIDEKEL, HWAN-CHING TAI, SABINE ARNDT
  • Patent number: 7842517
    Abstract: The invention provides methods and compositions for the rapid and sensitive detection of post-translationally modified proteins, and particularly of those with post-translational glycosylations. The methods can be used to detect O-GlcNAc posttranslational modifications on proteins on which such modifications were undetectable using other techniques. In one embodiment, the method exploits the ability of an engineered mutant of ?-1,4-galactosyltransferase to selectively transfer an unnatural ketone functionality onto O-GlcNAc glycosylated proteins. Once transferred, the ketone moiety serves as a versatile handle for the attachment of biotin, thereby enabling detection of the modified protein. The approach permits the rapid visualization of proteins that are at the limits of detection using traditional methods. Further, the preferred embodiments can be used for detection of certain disease states, such as cancer, Alzheimer's disease, neurodegeneration, cardiovascular disease, and diabetes.
    Type: Grant
    Filed: June 15, 2007
    Date of Patent: November 30, 2010
    Assignee: California Institute of Technology
    Inventors: Linda Hseih-Wilson, Nelly Khidekel, Hwan-Ching Tai, Sabine Arndt
  • Publication number: 20100041646
    Abstract: The present application relates to novel 1,4-phenylene-bis-oxazolidine derivatives, to processes for their preparation, to their use for the treatment and/or prophylaxis of diseases and also to their use for preparing medicaments for the treatment and/or prophylaxis of diseases, in particular thromboembolic disorders.
    Type: Application
    Filed: October 20, 2006
    Publication date: February 18, 2010
    Applicant: BAYER HEALTHCARE AG
    Inventors: Susanne Rohrig, Jens Pohlmann, Sabine Arndt, Mario Jeske, Metin Akbaba, Elisabeth Perzborn, Christoph Gerdes, Karl-Heinz Schlemmer
  • Publication number: 20080312424
    Abstract: The invention provides methods and compositions for the rapid and sensitive detection of post-translationally modified proteins, and particularly of those with post-translational glycosylations. The methods can be used to detect O-GlcNAc posttranslational modifications on proteins on which such modifications were undetectable using other techniques. In one embodiment, the method exploits the ability of an engineered mutant of ?-1,4-galactosyltransferase to selectively transfer an unnatural ketone functionality onto O-GlcNAc glycosylated proteins. Once transferred, the ketone moiety serves as a versatile handle for the attachment of biotin, thereby enabling detection of the modified protein. The approach permits the rapid visualization of proteins that are at the limits of detection using traditional methods. Further, the preferred embodiments can be used for detection of certain disease states, such as cancer, Alzheimer's disease, neurodegeneration, cardiovascular disease, and diabetes.
    Type: Application
    Filed: June 15, 2007
    Publication date: December 18, 2008
    Applicant: INVITROGEN CORPORATION
    Inventors: Linda Hseih-Wilson, Nelly Khidekel, Hwan-Ching Tai, Sabine Arndt
  • Publication number: 20080269300
    Abstract: The present application relates to novel phenylaminothiazole derivatives, to processes for their preparation, to their use for the treatment and/or prophylaxis of diseases and to their use for preparing medicaments for the treatment and/or prophylaxis of diseases, preferably for the treatment and/or prevention of hypertension and other cardiovascular disorders.
    Type: Application
    Filed: August 30, 2005
    Publication date: October 30, 2008
    Applicant: Bayer HealthCare AG
    Inventors: Jens-Kerim Erguden, Gunter Karig, Ulrich Rosentreter, Barbara Albrecht, Kerstin Henninger, Joachim Hutter, Nicole Diedrichs, Peter Nell, Sabine Arndt, Walter Hubsch, Andreas Knorr, Karl-Heinz Schlemmer, Dirk Brohm
  • Publication number: 20080214533
    Abstract: The invention relates to novel cyclic iminocarbamates of formula (I), wherein R1, R2, R3, A, Z, and n have the meanings recited in the description, to a method for the production thereof, to pharmaceutical compositions containing such materials, and to methods for the treatment and/or prophylaxis of thromboembolic diseases using them.
    Type: Application
    Filed: November 22, 2005
    Publication date: September 4, 2008
    Applicant: BAYER HEALTHCARE AG
    Inventors: Susanne Rohrig, Jens Pohlmann, Sabine Arndt, Mario Jeske, Metin Akbaba, Elisabeth Perzborn, Christoph Gerdes, Karl-Heinz Schlemmer, Arounarith Tuch, Mario Lobell, Peter Nell, Nils Burkhardt
  • Patent number: 7332355
    Abstract: The invention provides methods and compositions for the rapid and sensitive detection of post-translationally modified proteins, and particularly of those with post-translational glycosylations. The methods can be used to detect O-GlcNAc post-translational modifications on proteins on which such modifications were undetectable using other techniques. In one embodiment, the method exploits the ability of an engineered mutant of ?-1,4-galactosyltransferase to selectively transfer an unnatural ketone functionality onto O-GlcNAc glycosylated proteins. Once transferred, the ketone moiety serves as a versatile handle for the attachment of biotin, thereby enabling detection of the modified protein. The approach permits the rapid visualization of proteins that are at the limits of detection using traditional methods. Further, the preferred embodiments can be used for detection of certain disease states, such as cancer, Alzheimer's disease, neurodegeneration, cardiovascular disease, and diabetes.
    Type: Grant
    Filed: November 17, 2004
    Date of Patent: February 19, 2008
    Assignee: California Institute of Technology
    Inventors: Linda Hsieh-Wilson, Nelly Khidekel, Hwan-Ching Tai, Sabine Arndt
  • Publication number: 20060287315
    Abstract: The present invention relates to novel pyridinedicarboxamides, to processes for their preparation, to their use for the treatment and/or prophylaxis of diseases and also to their use for preparing medicaments for the treatment and/or prophylaxis of diseases, in particular thromboembolic disorders.
    Type: Application
    Filed: December 8, 2005
    Publication date: December 21, 2006
    Applicant: Bayer HealthCare AG
    Inventors: Susanne Rohrig, Mario Jeske, Metin Akbaba, Ulrich Rosentreter, Stephen Boyer, Karin Fischer, Jens Pohlmann, Arounarith Tuch, Elisabeth Perzborn, Christoph Gerdes, Karl-Heinz Schlemmer, Nils Burkhardt, Swen Allerheiligen, Peter Nell, Sabine Arndt, Mario Lobell
  • Publication number: 20050130235
    Abstract: The invention provides methods and compositions for the rapid and sensitive detection of post-translationally modified proteins, and particularly of those with post-translational glycosylations. The methods can be used to detect O-GlcNAc posttranslational modifications on proteins on which such modifications were undetectable using other techniques. In one embodiment, the method exploits the ability of an engineered mutant of ?-1,4-galactosyltransferase to selectively transfer an unnatural ketone functionality onto O-GlcNAc glycosylated proteins. Once transferred, the ketone moiety serves as a versatile handle for the attachment of biotin, thereby enabling detection of the modified protein. The approach permits the rapid visualization of proteins that are at the limits of detection using traditional methods. Further, the preferred embodiments can be used for detection of certain disease states, such as cancer, Alzheimer's disease, neurodegeneration, cardiovascular disease, and diabetes.
    Type: Application
    Filed: November 17, 2004
    Publication date: June 16, 2005
    Inventors: Linda Hsieh-Wilson, Nelly Khidekel, Hwan-Ching Tai, Sabine Arndt